As an expression of that commitment, Pfizer has pledged to supply up to 480 million doses of its 13-valent pneumococcal conjugate vaccine through 2023 at a deeply discounted price to infants and young children in GAVI-eligible countries who are at the highest risk of dying from pneumococcal disease under the auspices of the Advance Market Commitment (AMC), an innovative program piloted by the GAVI Alliance.

The AMC is a public-private health funding program designed to create a sustainable marketplace, ensure an affordable and stable supply of pneumococcal vaccines at a steeply discounted price and stimulate the development and expansion of manufacturing capacity for vaccines specifically for the world’s poorest countries.

Pfizer was proud to introduce its vaccine into the childhood immunization program of a developing country within one year of its launch in the United States and European Union – a historic precedent given the average 10-15 year lag for introducing newer vaccines into developing countries following their introduction in industrialized nations. As of December 2011, Prevenar 13* is now available in more than 85 percent of countries which have launched pneumococcal immunization programs under the AMC with many additional launches planned.

A key component of Pfizer’s commitment to make true inroads toward global healthcare access is to work through private-public partnerships such as the AMC which are vital to accelerating the availability of affordable vaccines to those children who are most vulnerable.

*Prevenar 13 is also known as Prevnar 13 in the United States, Canada, and other select countries